TABLE 4.
Compound | H37Rv | MmpL3, G253E | MmpL3, G758A/G253E | ΔcydA | QcrB D317T | ATCC 3583 (INH resistance) | ATCC 35838 (Rif resistance) | ATCC 35826 (CS resistance) | DNA gyrase GyrA, A90V | DNA gyrase GyrA, G88C |
---|---|---|---|---|---|---|---|---|---|---|
22 | 1.0 | 2.0 | 2.0 | 2.0 | 3.9 | 3.9 | 2.0 | 2.0 | 0.98 | 0.98 |
SQ109 (MmpL3 control) | 0.49 | 2.0 | 2.0 | |||||||
NITDS9 (ΔcydA and QcrB control) | 0.24 | 0.49 | 0.98 | |||||||
Moxifloxacin (GyrA control) | 0.24 | 7.8 | 0.49 | |||||||
Levofloxacin (GyrA control) | 0.49 | 16 | 2.0 | |||||||
Rif (Rif and universal control) | 0.002 | 0.001 | 0.001 | 0.0046 | 0.0046 | 0.006 | >0.1 | 0.001 | 0.0023 | 0.0023 |
Isoniazid (INH control) | 3.95 | >62.5 | 7.8 | 3.4 |
INH, isoniazid; Rif, rifampicin; CS, cycloserine.